Business ❯Healthcare Industry

Biotechnology

Pharmaceuticals Adaptimmune Psychedelic Companies Pharmaceutical Companies Purification Products Regulatory Agencies

FDA Rejects Aldeyra's Reproxalap NDA for Dry Eye Disease Over Efficacy Issues

The decision marks the second rejection of the drug application, with Aldeyra planning a mid-2025 resubmission pending new trial results.

Thermo Fisher Acquires Solventum’s Purification Unit for $4.1 Billion

FDA Approves Adaptimmune's Groundbreaking T-Cell Therapy for Rare Cancer